Klotho Neurosciences director granted 350,000 shares

McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/06/2026 - 03:25 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.

Klotho Neurosciences, Inc. director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were granted under the company’s Equity Incentive Plan and carried a reported price of $0.00 per share, indicating a non-cash equity award. Following this grant, McGarity’s directly held Common Stock increased to 411,277 shares, aligning his compensation more closely with shareholder interests through additional stock-based incentives.

Insider Trade Summary

Grant/Award: 350,000 shares

Grant/Award 1 txn

Insider McGarity Jon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	350,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 411,277 shares (Direct)

Footnotes (1)

1. F1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Klotho Neurosciences (KLTO) report for Jon McGarity?

Klotho Neurosciences director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock. The award was structured as an equity grant, not a cash purchase, and was made under the company’s Equity Incentive Plan on March 4, 2026.

How many Klotho Neurosciences (KLTO) shares does Jon McGarity hold after the latest grant?

After receiving the 350,000-share grant, Jon McGarity directly holds 411,277 shares of Klotho Neurosciences Common Stock. This total reflects his updated beneficial ownership position as reported in the Form 4 insider filing following the equity award.

Was Jon McGarity’s Klotho Neurosciences (KLTO) transaction a stock purchase or an equity grant?

The transaction was an equity grant, not an open-market stock purchase. Jon McGarity received 350,000 shares at a reported price of $0.00 per share as a grant under Klotho Neurosciences’ Equity Incentive Plan, classified as a grant, award, or other acquisition.

On what date did Jon McGarity receive his latest Klotho Neurosciences (KLTO) share grant?

Jon McGarity received the 350,000-share grant of Klotho Neurosciences Common Stock on March 4, 2026. This date is recorded as the transaction date in the Form 4 and marks when the equity award under the company’s Equity Incentive Plan was granted.

What type of security did Jon McGarity acquire from Klotho Neurosciences (KLTO)?

Jon McGarity acquired Common Stock of Klotho Neurosciences. The Form 4 reports a non-derivative transaction involving a grant of 350,000 shares of Common Stock issued under the company’s Equity Incentive Plan, increasing his directly held Common Stock position.

How is Jon McGarity’s Klotho Neurosciences (KLTO) share grant classified in the Form 4?

The share grant is classified with transaction code “A,” indicating a grant, award, or other acquisition. It is recorded as a non-derivative transaction, described as a grant of 350,000 shares of Common Stock under Klotho Neurosciences’ Equity Incentive Plan at a $0.00 price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGarity Jon

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		350,000	A	(1)	411,277	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

Remarks:

	Jon McGarity	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.